mifepristone has been researched along with medroxyprogesterone in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (33.33) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Chen, R; Gao, JG; Mazella, J; Powell, DR; Tseng, L; Zhu, HH | 1 |
| Elias, J; Huang, JR; Mazela, J; Tseng, L; Zhu, HH | 1 |
| Bischof, P; Brioschi, PA; Herrmann, WL; Tseng, L | 1 |
| Chen, G; Huang, JR; Mazella, J; Tseng, L | 1 |
| Fujimoto, J; Fujita, H; Hosoda, S; Okada, H | 1 |
| Mazella, J; Sun, B; Tseng, L | 1 |
| Beuving, DC; Campbell, JA; Gibson, RE; Spilman, CH | 1 |
| Okada, H | 1 |
| Barengolts, EI; Lathon, PV; Lindh, FG | 1 |
| Chao, V; Dreher, E; Mueller, MD; Pritts, EA; Taylor, RN; Vigne, JL | 1 |
| Hu, YZ; Yao, TW | 1 |
| Jaeger, R; Moe, BT; Orbo, A; Sager, G; Vereide, AB | 1 |
| Daikoku, E; Ito, S; Kuwabara, H; Mori, H; Nakahari, T; Nakano, T; Nishimura, A; Ohmichi, M; Sakuma, K; Shimamoto, C; Ueki, M; Ushiroyama, T | 1 |
| Hassell, J; Hiegel, C; Miryala, CS; Uphouse, L | 1 |
| Bořík, A; Golovko, O; Grabic, R; Kroupová, HK; Šauer, P; Stará, A; Valentová, O | 1 |
1 review(s) available for mifepristone and medroxyprogesterone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
17 other study(ies) available for mifepristone and medroxyprogesterone
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Effect of progestin, antiprogestin, and relaxin on the accumulation of prolactin and insulin-like growth factor-binding protein-1 messenger ribonucleic acid in human endometrial stromal cells.
Topics: Base Sequence; Blotting, Northern; Carrier Proteins; Endometrium; Female; Humans; Insulin-Like Growth Factor Binding Protein 1; Medroxyprogesterone; Medroxyprogesterone Acetate; Mifepristone; Molecular Sequence Data; Prolactin; Relaxin; RNA, Messenger; Transcription, Genetic | 1992 |
Progestin stimulates the biosynthesis of fibronectin and accumulation of fibronectin mRNA in human endometrial stromal cells.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Endometrium; Female; Fibronectins; Fluorescent Antibody Technique; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Mifepristone; Relaxin; RNA, Messenger | 1992 |
Cancer antigen 125 is produced by human endometrial stromal cells.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Cells, Cultured; Cycloheximide; Danazol; Endometriosis; Endometrium; Epitopes; Estradiol; Estrenes; Female; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Mifepristone; Triptorelin Pamoate | 1986 |
Long-term effects of progestin and RU 486 on prolactin production and synthesis in human endometrial stromal cells.
Topics: Adult; Cell Division; Cells, Cultured; DNA; Endometrium; Estrenes; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Mifepristone; Progestins; Prolactin | 1989 |
Mechanism of antitumoral activity of medroxyprogesterone acetate for endometrial cancer.
Topics: Antineoplastic Agents; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Mifepristone; Norethindrone; Receptors, Progesterone; Tumor Cells, Cultured; Tumor Stem Cell Assay; Uterine Neoplasms | 1989 |
Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen and RU 486.
Topics: Adult; Aromatase; Dexamethasone; Dose-Response Relationship, Drug; Endometrium; Estrenes; Female; Humans; Hydrocortisone; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Mifepristone; Norethindrone; Progesterone; Progestins; Promegestone; Steroids; Tamoxifen; Testosterone; Time Factors | 1986 |
Progestin and antiprogestin effects on progesterone receptor transformation.
Topics: Animals; Desoxycorticosterone; Estrenes; Female; Hydroxyprogesterones; Medroxyprogesterone; Medroxyprogesterone Acetate; Mifepristone; Molybdenum; Progestins; Promegestone; Protein Conformation; Rabbits; Receptors, Progesterone | 1986 |
[Progestogen therapy in the treatment of endometrial cancer--clinical results and mechanism of steroid action].
Topics: Estrenes; Female; Humans; In Vitro Techniques; Medroxyprogesterone; Medroxyprogesterone Acetate; Mifepristone; Neoplasms, Hormone-Dependent; Norethindrone; Norgestrel; Progesterone Congeners; Receptors, Progesterone; Tumor Stem Cell Assay; Uterine Neoplasms | 1988 |
Progesterone antagonist RU 486 has bone-sparing effects in ovariectomized rats.
Topics: Analysis of Variance; Animals; Bone Density; Bone Resorption; Drug Interactions; Drug Therapy, Combination; Female; Hormone Antagonists; Humans; Injections, Intramuscular; Injections, Subcutaneous; Medroxyprogesterone; Mifepristone; Osteoporosis, Postmenopausal; Ovariectomy; Progesterone Congeners; Random Allocation; Rats; Rats, Sprague-Dawley; Tibia | 1995 |
Progestins activate vascular endothelial growth factor gene transcription in endometrial adenocarcinoma cells.
Topics: Adenocarcinoma; Endometrial Neoplasms; Endothelial Growth Factors; Female; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Medroxyprogesterone; Mifepristone; Promegestone; Receptors, Progesterone; Transcription, Genetic; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[In vitro metabolic interaction between diphenytriazol and steroid hormone drugs].
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Animals; Contraceptives, Oral, Synthetic; Drug Interactions; Estradiol; Female; In Vitro Techniques; Medroxyprogesterone; Microsomes, Liver; Mifepristone; Rats; Rats, Sprague-Dawley; Triazoles | 2006 |
Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Contraceptives, Oral, Synthetic; Dose-Response Relationship, Drug; Drug Synergism; Endometrial Neoplasms; Female; Humans; Levonorgestrel; Medroxyprogesterone; Mifepristone; Progesterone; Progestins; Receptors, Progesterone | 2009 |
Ciliary beat frequency controlled by oestradiol and progesterone during ovarian cycle in guinea-pig Fallopian tube.
Topics: Animals; Cilia; Estradiol; Estrous Cycle; Fallopian Tubes; Female; Fulvestrant; Guinea Pigs; Medroxyprogesterone; Microscopy, Video; Mifepristone; Ovulation; Progesterone; Receptors, Estradiol; Receptors, Progesterone | 2010 |
Mechanisms responsible for progesterone's protection against lordosis-inhibiting effects of restraint I. Role of progesterone receptors.
Topics: Animals; Estradiol; Estrogens; Female; Hormone Antagonists; Medroxyprogesterone; Mifepristone; Ovariectomy; Posture; Progesterone; Progestins; Rats; Rats, Inbred F344; Receptors, Progesterone; Restraint, Physical; Sexual Behavior, Animal | 2011 |
Two synthetic progestins and natural progesterone are responsible for most of the progestagenic activities in municipal wastewater treatment plant effluents in the Czech and Slovak republics.
Topics: Cell Line; Czech Republic; Ecotoxicology; Environmental Monitoring; Humans; Medroxyprogesterone; Mifepristone; Progesterone; Progestins; Receptors, Progesterone; Slovakia; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2018 |